1Board of Governor’s Regenerative Medicine Institute,Cedars-Sinai Medical Center, 2Center for Neural Sciences in Medicine,Cedars-Sinai Medical Center, 3Department of Biomedical Sciences,Cedars-Sinai Medical Center, 4Samuel Oschin Comprehensive Cancer Institute,Cedars-Sinai Medical Center, 5Department of Medicine, David Geffen School of Medicine,University of California, Los Angeles
Utilizing an immunocompetent, autochthonous tumor model driven by common patient mutations for preclinical testing is critical for immunotherapeutic testing. This protocol describes a method to generate brain tumor mouse models using electroporation-based delivery of plasmid DNA that represent common patient mutations, thus providing an accurate, reproducible, and consistent mouse model.
